阿司匹林对老年冠心病患者血清C反应蛋白水平的影响被引量：3

Serum C-reactive protein levels in elder patients with coronary heart disease and effect of aspirin intervention

导出

摘要目的观察老年冠心病患者(CHD组)血清C反应蛋白(CRP)水平及应用不同剂量阿司匹林治疗后其血清CRP水平的变化。方法将90例老年冠心病患者随机分为阿司匹林100 mg/d组(CHD1组)、150mg/d组(CHD2组)、200 mg/d(CHD3组),另设正常对照组(对照组),每组均为30例。测定对照组及90例冠心病患者应用阿司匹林治疗前和治疗后12周时的血清CRP水平。结果CHD组的CRP水平较对照组明显升高(P<0.05),CHD2组、CHD3组经阿司匹林治疗后血清CRP水平较CHD1组明显降低(P<0.05)。结论老年冠心病患者血清CRP水平升高,阿司匹林干预治疗可降低冠心病患者血清CRP水平,提示冠心病的发生发展过程与炎症有关,而阿司匹林可呈剂量相关地通过抗炎作用抑制其进展,效应以150 mg以上为佳。 Objective To investigate the serum C-reactive protein（CRP） concentrations in elder patients with coronary heart disease（CHD） and the change of serum CRP concentrations in patients with CHD treated with aspirin. Methods Ninety eider patients with CHD were administered aspirin at the dose of 100mg/d （CHD1 group）, 150mg/d（ CHD2 group）, 200mg/d（CHD3 group）. Normal subjects were selected as control（control group）, there were thirty subjects in each group. The detected parameters included serum CRP concentrations for 0 and 12 weeks. Results CRP concentration in patients with coronary heart disease was significantly higher than that of the normal subjects（P 〈 0.05）. CRP concentration in patients with CHD could reduce with aspirin 150mg/d, 200mg/d for 12 weeks（P 〈 0.05）. Conclusion The serum CRP concentration is associated with patients with CHD, the serum CRP concentration could reduced with bigger dosage of aspirin. The occurance and development of CHD is correlative to inflammation,aspirin could dose-dependantly attenuate the progression of CHD.

作者刘尝君谭小颖陈树丹

机构地区惠州市中心人民医院老年病科

出处《中国基层医药》 CAS 2006年第2期243-245,共3页 Chinese Journal of Primary Medicine and Pharmacy

关键词冠状动脉疾病 C反应蛋白阿司匹林炎症老年人冠心病 Coronary disease C-reactive protein Aspirin Inflammation Aged

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献14

1Willerson JT. Systemic and local inflammation in patients with unstable at herosclerotic plaques. Prog Cardiovasc Dis, 2002,44 ( 6 ) : 469-478.
2Kervinen H, Palosuo T, Manninen V, et al. joint effects of C-reactive protein and other risk factors on acute coronary events. Am Heart J,2001,141(4) :581-585.
3Retterstol L, Eikvar L, Bohn M, et al. C-reactive protein predicts death in patients with previous premature myocardial infarction-A 10 years follow-up study. Atherosclerosis, 2002,160 (2) : 433-440.
4Morrow DA, Ridker PM. C-reacitve protein, inflammation, and coronary risk. Med Clin North Am, 2000,84( 1 ) : 149-161.
5Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothlial cells. Circulation, 2000, 102(18) :2165-2168.
6Haverkate F. Are C-reactive protein and fibringogen risk factor?. In:Vander Wall EE(eds). Vascular Medicine. Kluwer Academic Publishers. Printed in the Netherlands, 1997 : 13-21.
7Kuller LH,Tracy RP, Shaten j, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study.Am L Epidemiol, 1996,144(6) :537-547.
8Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reacitve protein and the risk of future cardiovascular events among apparently healthy women. Circulation, 1998,98 ( 8 ) : 731-733.
9Belton O, Byme D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation, 2000,102 ( 8 ) : 840-845.
10Voisarcl R, Fischer R, Obwald M, et al. Aspirin (5mmool/L) inhibits leukocyte attack and triggered reactive cell proliferation in a 3D human coronary in vitro model. Cireulation ,2001,103(12) : 1688-1694.